Nitric oxide in physiology and pathology of metabolism;Tlenek azotu w fizjologii i patologii metabolizmu

Polski Merkuriusz Lekarski

Volumn 18, Issue 103, 2005, Pages 101-104

  Glinianowicz Olszanecka, Magdalena ^a   Zahorska Markiewicz, Barbara ^a   Zurakowski, Aleksander ^a   Glinianowicz, Mariusz ^a  

^a SILESIAN UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Insulin resistance; Lipolysis; Nitric oxide

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE;

ADIPOSE TISSUE; AUTOCRINE EFFECT; DYSLIPIDEMIA; ENZYME ACTIVITY; HUMAN; INSULIN RESISTANCE; LIPOLYSIS; METABOLIC DISORDER; METABOLIC REGULATION; OBESITY; PARACRINE SIGNALING; PATHOPHYSIOLOGY; REVIEW;

ADIPOSE TISSUE; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; OBESITY; UP-REGULATION;

EID: 13444262496     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Andersson K. i wsp.: A nitric oxide-mediated mechanism regulates lipolysis in human adipose tissue in vivo. Br. J. Pharmacol., 1999, 126, 6, 1639-1645.
2. Anfossi G. i wsp.: Platelet resistance to nitrates in obesity and obese NO platelet sensitivity to both insulin and nitrates in lean. Diabetes Care, 1998, 21, 1, 121-126.
3. Baron A.D. Insulin and the vasculature-old actors, new roles. J. Investig. Med., 1996, 44, 8, 406-412.
4. Baron A.D.: The coupling of glucose metabolism and perfusion in human skeletal muscle the potential role of endotelium-derived nitric oxide. Diabetes, 1996, 45, Suppl. 1, 105-109.
5. Cardillo C. i wsp.: Vasodilator response to systemic but not to local hiperinsulinemia in the human forearm. Hypertension, 1998, 32, 6, 12-13.
6. Choi J.W. i wsp.: Increases in nitric oxide concentrations correlate strongly with body fat in obese humans. Clin. Chem., 2001, 47, 1106-1109.
7. Christopherson K.S., Bredt D.S.: Nitric oxide in excitable tissues: physiological roles and disease. J. Clin. Invest., 1997, 100, 10, 2424-2429.
8. Cleland S.J. i wsp.: Insulin action is associated with endothelial function in hypertension and type 2 diabetes. Hypertension, 2000, 35, 1, 507-511.
9. Coiro V. i wsp.: Involvement of nitric oxide in arginine, but not glucose, induced insulin secretion in normal men. Clin. Endocrinol., 1997, 46, 1, 115-119.
10. Dembińska-Kieć A.: Miażdżyca naczyń jako odpowiedż immunologiczna ustroju. udział tlenku azotu, NO. Acta Angiol., 1995, 1, 1, 5-14.
11. Elizalde M. i wsp.: Expresion of nitric oxide syntheses in subcutaneous adipose tissue of nonobese and obese humans. J. Lipid Res., 2000, 41, 1244-1251.
12. Esaki T. i wsp.: Expression of inducible nitric oxide synthase in T lymphocytes and macrophages of cholesterol-fed rabbits. Atherosclerosis, 1997, 128, 1, 39-46.
13. Gaudiot N. i wsp.: Endogenous nitric oxide is implicated in the regulation of lipolysis through antioxidant-related effect. Am. J. Physiol. Cell. Physiol., 2000, 279, 1603-1610.
14. Gaudiot N. i wsp.: Modulation of white adipose tissue lipolysis by nitric oxide. J. Biol. Chem., 1998, 273, 13475-13481.
15. Gryglewski R.: Biologiczna rola śródbłonkowego tlenku azotu. Czynn. Ryz., 1998, 4, 9-11.
16. Jordan J. i wsp.: Interaction between b-adrenergic receptor stimulation and nitric oxide release on tissue perfusion and metabolism. J. Clin. Endocrynol. Metab., 2001, 86, 6, 2803-2810.
17. Kapur S. i wsp.: Nitric oxide: a new player in the modulation of energy metabolism. Intern. J. Obes., 2000, 24, suppl. 4, 36-40.
18. von Knethen A. i wsp.: NFKB and AP-1 activation by nitric oxide attenuated apoptotic cell death in RAW 264.7 macrophages. MBC, 1999, 10, 2, 361-372.
19. Michel T., Feron O.: Nitric oxide syntheses which, where, how, and why? J. Clin. Invest., 1997, 100, 9, 2146-2152.
20. Morley J. E.: An overview of diabetes mellitus in older persons. Clin. Geriatr. Med., 1999, 15, 2, 211-224.
21. Paolisso G. i wsp. L -arginine but not D-arginine stimulates insulin-mediated glucose uptake. Metab., 1997, 46, 9, 1068-1073.
22. Piatti P.M. i wsp.: Alterations in nitric oxide / cyclic-CMP pathway in non-diabetic siblings of patients with type 2 diabetes. J. Clin. Endocrinol. Metab., 2000, 85, 7, 2416-2420.
23. Raitakari O.T. i wsp.: Enhanced peripheral vasodilation in humans after a fatty meal. J. Am. Coll. Cardiol., 2000, 36, 2, 417-422.
24. Ribiere C. i wsp.: White adipose tissue nitric oxide synthase: a potential source for NO production. Biochem. Biophys. Res. Commun., 1996, 222, 706-712.
25. Ricciardolo F.L.M.: Multiple roles of nitric oxide in the airways. Thorax, 2003, 58, 175-182.
26. Ryden M. i wsp.: Increased expression of eNOS protein in omental versus subcutaneous adipose tissue in obese human subjects. Intern. J. Obes., 2001, 25, 811-815.
27. Stamler J.S. i wsp.: S-nitrosylation of proteins with nitric oxide synthesis and characterization of biologically active compounds. Proc. Natl. Acad. Sci., 1992, 89, 444-448.
28. Stefano G.B. i wsp.: Cyclic nitric oxide release by human granulocytes, and invertebrate ganglia and immunocytes nano-technological enhancement of amperometric nitric oxide determination. Med. Sci. Monit., 2002, 8, 6, 199-204.
29. Williams I.L. i wsp.: Obesity, atherosclerosis and the vascular endothelium mechanisms of reduced nitric oxide bioavailability in obese humans. Intern. J. Obes., 2002, 26, 754-764.
30. Vallance P., Collier J.: Fortnightly review biology and clinical relevance of nitric oxide. BMJ, 1994, 309, 453-457.